Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.
B Coiffier, F Reyes - Oncology (Williston Park, NY), 2005 - europepmc.org
The Groupe d'Etude des Lymphomes de l'Adulte (GELA) has conducted several phase II
and III studies in patients with aggressive lymphoma, diffuse large B-cell lymphoma …
and III studies in patients with aggressive lymphoma, diffuse large B-cell lymphoma …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - The Lancet, 2019 - thelancet.com
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas …
M Pfreundschuh, L Trümper, M Kloess, R Schmits… - Blood, 2004 - ashpublications.org
The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given
every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. To …
every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. To …
Successful application of a previously derived prognostic index in the analysis of a randomised trial of 281 patients with high grade non-Hodgkin's lymphoma …
RCF Leonard, RJ Prescott, JH Mao, JM White - Annals of oncology, 1993 - Elsevier
Background The selection of patients for experimental therapies for high grade non-
Hodgkin's lymphoma (NHL) is now recognised to be very influential in affecting results. We …
Hodgkin's lymphoma (NHL) is now recognised to be very influential in affecting results. We …
[HTML][HTML] Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
SA Gregory, L Trümper - Annals of oncology, 2005 - Elsevier
Background: Higher chemotherapy dose intensity has been studied as a way of improving
the clinical outcomes in various malignancies, including non-Hodgkin's lymphoma (NHL) …
the clinical outcomes in various malignancies, including non-Hodgkin's lymphoma (NHL) …
Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) with or without rituximab as first-line therapy for aggressive non …
ZS Lamar, N Fino, J Palmer, L Gruber, BB Morris… - … Myeloma and Leukemia, 2016 - Elsevier
Introduction Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and
doxorubicin (DA-EPOCH) was developed in an effort to overcome inadequate drug …
doxorubicin (DA-EPOCH) was developed in an effort to overcome inadequate drug …
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with …
C Buske, E Hoster, M Dreyling, H Eimermacher… - Leukemia, 2009 - nature.com
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to
conventional chemotherapy. This study investigated whether the addition of rituximab to …
conventional chemotherapy. This study investigated whether the addition of rituximab to …
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma
Background The efficacy of autologous stem-cell transplantation during the first remission in
patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate …
patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate …
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate …
P Morel, JN Munck, B Coiffier, C Gisselbrecht… - Leukemia & …, 2010 - Taylor & Francis
One-third of patients aged≤ 60 years with aggressive lymphoma are at low–intermediate
risk (LIR). Before the rituximab era, we prospectively compared ACVBP with ECVBP, a …
risk (LIR). Before the rituximab era, we prospectively compared ACVBP with ECVBP, a …
[HTML][HTML] Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.
L Hicks, R Buckstein, J Mangel, E Piliotis, K Imrie… - Blood, 2006 - Elsevier
Background: Patients with relapsed or refractory aggressive B-cell lymphoma, or
transformed indolent lymphoma can achieve long-term survival with high dose therapy and …
transformed indolent lymphoma can achieve long-term survival with high dose therapy and …